137 related articles for article (PubMed ID: 24114941)
1. Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment.
Chen CK; Yang CY; Hua KT; Ho MC; Johansson G; Jeng YM; Chen CN; Chen MW; Lee WJ; Su JL; Lai TC; Chou CC; Ho BC; Chang CF; Lee PH; Chang KJ; Hsiao M; Lin MT; Kuo ML
Hepatology; 2014 Mar; 59(3):974-85. PubMed ID: 24114941
[TBL] [Abstract][Full Text] [Related]
2. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
3. The tumor suppressor function of LECT2 in human hepatocellular carcinoma makes it a potential therapeutic target.
Ong HT; Tan PK; Wang SM; Hian Low DT; Ooi LL; Hui KM
Cancer Gene Ther; 2011 Jun; 18(6):399-406. PubMed ID: 21394108
[TBL] [Abstract][Full Text] [Related]
4. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
Tan S; Li R; Ding K; Lobie PE; Zhu T
FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis.
Chen CK; Yu WH; Cheng TY; Chen MW; Su CY; Yang YC; Kuo TC; Lin MT; Huang YC; Hsiao M; Hua KT; Hung MC; Kuo ML
Sci Rep; 2016 Aug; 6():31398. PubMed ID: 27507763
[TBL] [Abstract][Full Text] [Related]
6. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma.
Chu TH; Ko CY; Tai PH; Chang YC; Huang CC; Wu TY; Chan HH; Wu PH; Weng CH; Lin YW; Kung ML; Fang CC; Wu JC; Wen ZH; Lee YK; Hu TH; Tai MH
J Biol Chem; 2022 Oct; 298(10):102442. PubMed ID: 36055405
[TBL] [Abstract][Full Text] [Related]
8. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.
Gui Y; Yeganeh M; Donates YC; Tobelaim WS; Chababi W; Mayhue M; Yoshimura A; Ramanathan S; Saucier C; Ilangumaran S
Oncogene; 2015 Nov; 34(46):5718-28. PubMed ID: 25728680
[TBL] [Abstract][Full Text] [Related]
9. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion.
Kaufmann R; Oettel C; Horn A; Halbhuber KJ; Eitner A; Krieg R; Katenkamp K; Henklein P; Westermann M; Böhmer FD; Ramachandran R; Saifeddine M; Hollenberg MD; Settmacher U
Carcinogenesis; 2009 Sep; 30(9):1487-96. PubMed ID: 19546160
[TBL] [Abstract][Full Text] [Related]
10. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma.
Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
Hepatology; 1997 Mar; 25(3):619-23. PubMed ID: 9049208
[TBL] [Abstract][Full Text] [Related]
11. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization.
Wu YM; Liu CH; Huang MJ; Lai HS; Lee PH; Hu RH; Huang MC
Cancer Res; 2013 Sep; 73(17):5580-90. PubMed ID: 23832667
[TBL] [Abstract][Full Text] [Related]
12. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
[TBL] [Abstract][Full Text] [Related]
13. Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma.
Okabe H; Delgado E; Lee JM; Yang J; Kinoshita H; Hayashi H; Tsung A; Behari J; Beppu T; Baba H; Monga SP
PLoS One; 2014; 9(6):e98817. PubMed ID: 24892551
[TBL] [Abstract][Full Text] [Related]
14. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
15. C-met and hepatocyte growth factor expression in combined hepatocellular and cholangiocarcinoma.
Varnholt H; Asayama Y; Aishima S; Taguchi K; Sugimachi K; Tsuneyoshi M
Oncol Rep; 2002; 9(1):35-41. PubMed ID: 11748452
[TBL] [Abstract][Full Text] [Related]
16. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver.
Ovejero C; Cavard C; Périanin A; Hakvoort T; Vermeulen J; Godard C; Fabre M; Chafey P; Suzuki K; Romagnolo B; Yamagoe S; Perret C
Hepatology; 2004 Jul; 40(1):167-76. PubMed ID: 15239100
[TBL] [Abstract][Full Text] [Related]
17. Expression pattern of a newly recognized protein, LECT2, in hepatocellular carcinoma and its premalignant lesion.
Uchida T; Nagai H; Gotoh K; Kanagawa H; Kouyama H; Kawanishi T; Mima S; Yamagoe S; Suzuki K
Pathol Int; 1999 Feb; 49(2):147-51. PubMed ID: 10355968
[TBL] [Abstract][Full Text] [Related]
18. Leukocyte cell-derived chemotaxin 2 is an antiviral regulator acting through the proto-oncogene MET.
Shirasaki T; Yamagoe S; Shimakami T; Murai K; Imamura R; Ishii KA; Takayama H; Matsumoto Y; Tajima-Shirasaki N; Nagata N; Shimizu R; Yamanaka S; Abe A; Omura H; Kawaguchi K; Okada H; Yamashita T; Yoshikawa T; Takimoto K; Taharaguchi M; Takatsuka S; Miyazaki Y; Tamai T; Tanabe Y; Kurachi M; Yamamoto Y; Kaneko S; Matsumoto K; Takamura T; Honda M
Nat Commun; 2022 Jun; 13(1):3176. PubMed ID: 35676290
[TBL] [Abstract][Full Text] [Related]
19. Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1.
Jiang Y; Xu W; Lu J; He F; Yang X
Biochem Biophys Res Commun; 2001 Sep; 286(5):1123-30. PubMed ID: 11527416
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of cMet tyrosine residues in murine ascitic hepatic cancer cell lines with different lymph node metastatic potentials.
Li Y; Huang X; Zhang Q; Ma K
Mol Med Rep; 2013 Aug; 8(2):655-61. PubMed ID: 23778885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
